Patient with hypertriglyceridemia, type 2 diabetes, and chronic kidney disease treated with atorvastatin and omega-3 Fatty Acid ethyl esters (Q36310496)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Patient with hypertriglyceridemia, type 2 diabetes, and chronic kidney disease treated with atorvastatin and omega-3 Fatty Acid ethyl esters	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

13 August 2017

Patient with hypertriglyceridemia, type 2 diabetes, and chronic kidney disease treated with atorvastatin and omega-3 Fatty Acid ethyl esters (English)

1 reference

Europe PubMed Central

13 August 2017

0 references

type 2 diabetes

1 reference

based on heuristic

inferred from title

hypertriglyceridemia

1 reference

based on heuristic

inferred from title

chronic renal insufficiency

1 reference

based on heuristic

inferred from title

Dimitri P Mikhailidis

2

object named as

Dimitri P Mikhailidis

1 reference

Europe PubMed Central

13 August 2017

author name string

Vasilios G Athyros

1

1 reference

Europe PubMed Central

13 August 2017

publication date

20 September 2012

1 reference

Europe PubMed Central

13 August 2017

Open Cardiovascular Medicine Journal

1 reference

Europe PubMed Central

13 August 2017

6

1 reference

Europe PubMed Central

13 August 2017

122-125

1 reference

Europe PubMed Central

13 August 2017

copyright license

Creative Commons Attribution-NonCommercial 3.0 Unported

20 September 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

Is there a role for hypolipidaemic drug therapy in the prevention or treatment of microvascular complications of diabetes?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3468870

30 September 2017

IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3468870

30 September 2017

Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3468870

30 September 2017

Clinical features of cardio-renal syndrome in a cohort of consecutive patients admitted to an internal medicine ward

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3468870

30 September 2017

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3468870

30 September 2017

Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3468870

30 September 2017

Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3468870

30 September 2017

Kidney function and estimated vascular risk in patients with primary dyslipidemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3468870

30 September 2017

HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3468870

30 September 2017

Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3468870

30 September 2017

Omega-3 fatty acids: how can they be used in secondary prevention?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3468870

30 September 2017

Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3468870

30 September 2017

The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3468870

30 September 2017

Safety of statins: focus on clinical pharmacokinetics and drug interactions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3468870

30 September 2017

An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3468870

30 September 2017

Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. But what about the amiodarone?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3468870

22 September 2018

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3468870

22 September 2018

Statins and renal function in patients with diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3468870

22 September 2018

Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3468870

22 September 2018

Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3468870

22 September 2018

Effects of a National Cholesterol Education Program Step II Diet on apolipoprotein A-IV metabolism within triacylglycerol-rich lipoproteins and plasma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3468870

22 September 2018

Effects of National Cholesterol Education Program Step 2 diets relatively high or relatively low in fish-derived fatty acids on plasma lipoproteins in middle-aged and elderly subjects.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3468870

22 September 2018

Editorial: should chronic kidney disease be considered as a coronary heart disease equivalent?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23066433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atherogenesis in renal patients: a model of vascular disease?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23066433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of cholesterol-lowering treatment on renal function

1 reference

https://pubmed.ncbi.nlm.nih.gov/23066433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Stage of chronic kidney disease and severity of coronary heart disease manifestation

1 reference

https://pubmed.ncbi.nlm.nih.gov/23066433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23066433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Statin treatment may be beneficial to both the kidneys and the heart

1 reference

https://pubmed.ncbi.nlm.nih.gov/23066433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Statins and renal function. Is the compound and dose making a difference?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23066433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Statins in patients with renal dysfunction

1 reference

https://pubmed.ncbi.nlm.nih.gov/23066433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2174/1874192401206010122

1 reference

Europe PubMed Central

13 August 2017

1 reference

Europe PubMed Central

13 August 2017

1 reference

Europe PubMed Central

13 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36310496&oldid=1800299705"